Hematopoiesis News Volume 11.05 | Feb 11 2020

TOP STORY

Live-Animal Imaging of Native Hematopoietic Stem and Progenitor Cells

Researchers describe a dual genetic strategy in mice that restricted reporter labeling to a subset of the most quiescent long-term HSCs and that was compatible with current intravital imaging approaches in the calvarial bone marrow. [Nature] Abstract

(Ranked by impact factor of the journal)

Cxcr4 Distinguishes HSC-Derived Monocytes from Microglia and Reveals Monocyte Immune Responses to Experimental Stroke

Scientists found that Cxcr4-CreER enabled permanent genetic labeling of HSCs and distinguished HSC-derived monocytes from microglia and other tissue-resident macrophages. [Nat Neurosci] Abstract

Single-Cell Transcriptomics Identifies CD44 as a Marker and Regulator of Endothelial to Hematopoietic Transition

Using single-cell transcriptome analysis and antibody screening, investigators identified CD44 as a marker of endothelial to hematopoietic transition (EHT) enabling them to isolate robustly the different stages of EHT in the aorta-gonad-mesonephros region. [Nat Commun] Full Article

YAP Regulates Hematopoietic Stem Cell Formation in Response to the Biomechanical Forces of Blood Flow

The authors devised a human dorsal aorta-on-a-chip platform that identified Yes-activated protein (YAP) as a cyclic stretch-induced regulator of hematopoietic stem and progenitor cell formation. [Dev Cell] Full Article | Graphical Abstract

Mobilization-Based Transplantation of Young-Donor Hematopoietic Stem Cells Extends Lifespan in Mice

Researchers replaced aged HSCs with young-donor HSCs using a novel mobilization-enabled HSC transplantation (HSCT) technology as an alternative to the highly toxic conditioning regimens used in conventional HSCT. [Aging Cell] Full Article

STAT5-Dependent Regulation of CDC25A by miR-16 Controls Proliferation and Differentiation in FLT3-ITD Acute Myeloid Leukemia

Scientists determined that miR-16 expression was repressed by FLT3-ITD activity, and that STAT5 participated in this repression. miR-16 expression was significantly reduced in a panel of AML primary samples carrying the FLT3-ITD mutation when compared with FLT3wt cells. [Sci Rep] Full Article

CLINICAL RESEARCH

Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?

Investigators compared outcomes of acute myeloid leukemia (AML) patients >60 years of age undergoing allogenic HSC transplantation at their institution. [Blood] Abstract

ATIR101 Administered after T-Cell-Depleted Haploidentical HSCT Reduces NRM and Improves Overall Survival in Acute Leukemia

Safety and efficacy of ATIR101 administered after T-cell-depleted haploidentical HSC transplantation (HSCT) without posttransplant immunosuppressors were evaluated in a Phase II, multicenter study of 23 patients with acute leukemia. [Leukemia] Full Article

Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with B-Cell Acute Lymphoblastic Leukemia Harboring t(1; 19)(q23; p13.3); Comparison with Normal Karyotype

Researchers used a nationwide registry data of Japan for 2003-2016 to evaluate transplant outcomes and clarified prognostic factors among adult allogeneic HSC transplantation recipients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3). [Bone Marrow Transplant] Abstract

Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News.

Curative Options for Sickle Cell Disease: Haploidentical Stem Cell Transplantation or Gene Therapy?

As improvements are made for alternative donors in the allogeneic setting and as data emerge from gene therapy trials, the optimal curative strategy for any individual patient with sickle cell disease will be determined by many critical factors including efficacy, transplant morbidity and mortality, safety, patient disease status and preference, cost and applicability. [Br J Haematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Da Volterra Announces Positive Top-Line Results from a Phase II Clinical Trial Evaluating DAV132 in 260 Patients

Da Volterra announced positive top-line results from a Phase II clinical trial, ‘SHIELD’, evaluating DAV132 in patients receiving fluoroquinolone antibiotics. DAV132 is a novel, first-in-class, orally administered, colon-targeted adsorbent designed to protect the intestinal microbiota of patients against antibiotic-induced disruption. [Da Volterra] Press Release

US FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma

Kite announced that the FDA has accepted the BLA and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. [Kite (Business Wire, Inc.)] Press Release

Trump’s 2021 Budget Drowns Science Agencies in Red Ink, Again

It’s another sea of red ink for federal research funding programs in President Donald Trump’s latest budget proposal. The 2021 budget request to Congress released February 10^th calls for deep, often double-digit cuts to R&D spending at major science agencies. [ScienceInsider] Editorial

Major Cancer Institute Sued by Its Own Researchers Over ‘Tapering’ Funding

Alleging that a leading cancer funder is slashing their support in an “unethical and reckless” way, six prominent cancer researchers at the University of California, San Diego, have filed a lawsuit to compel it to continue its current level of support. [ScienceInsider] Editorial

NEW Keystone Symposium: Tumor Metabolism
March 8-12, 2020
Banff, Alberta, Canada

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Plasma Cell Development and Functional Heterogeneity (Western Michigan University)

NEW Postdoctoral Fellow Positions – Hematopoietic Stem Cell Biology (Nationwide Children’s Hospital)

Scientist – Hematopoietic Stem and Progenitor Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Researcher – Bioinformatics and Leukemia Stem Cells (The Centre for Genomic Regulation)

Postdoctoral Fellow – Hereditary and Childhood Tumors (The University of British Columbia)

Postdoctoral Fellowship – Personalized Cancer Treatments (MGH Cancer Center)

Faculty Position – Cancer Epidemiology (MD Anderson Cancer Center)

Postdoctoral Fellow – Erythropoiesis (Mount Sinai School of Medicine)

Assistant/Associate Professor – Hematology & Oncology (UC Davis School of Medicine)

Associate/Professor – Hematology & Oncology (UC Davis School of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here.